ArticleJournal of the American Chemical Society2013
Mimicry of high-density lipoprotein: functional peptide-lipid nanoparticles based on multivalent peptide constructs.
Article in Journal of the American Chemical Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 74 citations in OpenAlex.
- Trifluoroacetate mediated reduction of atherosclerosis in mice.Nature communications · 2026Article
- Dexamethasone palmitate-loaded sHDL nanodiscs: Enhanced efficacy and safety in allergic conjunctivitis.Journal of pharmaceutical analysis · 2025Article
- Nano-formulations in disease therapy: designs, advances, challenges, and future directions.Journal of nanobiotechnology · 2025Review
- Solubilization of Phospholipid by Surfactin Leading to Lipid Nanodisc and Fibrous Architecture Formation.Molecules (Basel, Switzerland) · 2024Article
- Multivalent Display of ApoAI Peptides on the Surface of Tobacco Mosaic Virus Nanotubes Improves Cholesterol Efflux.Bioconjugate chemistry · 2022Article
- The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy.Aging and disease · 2022Review
- From design to clinic: Engineered peptide nanomaterials for cancer immunotherapy.Frontiers in chemistry · 2022Review
- Apolipoprotein Mimetic Peptide Inhibits Neutrophil-Driven Inflammatory Damage via Membrane Remodeling and Suppression of Cell Lysis.ACS nano · 2021Article
- Membrane active Janus-oligomers of βChemical science · 2020Article
- High density lipoprotein mimicking nanoparticles for atherosclerosis.Nano convergence · 2020Review
- Supramolecular Assembly of High-Density Lipoprotein Mimetic Nanoparticles Using Lipid-Conjugated Core Scaffolds.Journal of the American Chemical Society · 2019Article
- Characterization of apolipoprotein A-I peptide phospholipid interaction and its effect on HDL nanodisc assembly.International journal of nanomedicine · 2019Article
- Apoproteins E, A-I, and SAA in Macrophage Pathobiology Related to Atherogenesis.Frontiers in pharmacology · 2019Review
- Treating atherosclerosis: targeting risk factors should not be the only option.Annals of translational medicine · 2018Article
- DNA-Corralled Nanodiscs for the Structural and Functional Characterization of Membrane Proteins and Viral Entry.Journal of the American Chemical Society · 2018Article
- Lipid composition dictates serum stability of reconstituted high-density lipoproteins: implications for in vivo applications.Nanoscale · 2018Article
- High-density lipoprotein-mimicking nanodiscs carrying peptide for enhanced therapeutic angiogenesis in diabetic hindlimb ischemia.Biomaterials · 2018Article
- Effect of Synthetic High Density Lipoproteins Modification with Polyethylene Glycol on Pharmacokinetics and Pharmacodynamics.Molecular pharmaceutics · 2018Article
- Spontaneous Lipid Nanodisc Fomation by Amphiphilic Polymethacrylate Copolymers.Journal of the American Chemical Society · 2017Article
- A unique mid-sequence linker used to multimerize the lipid-phosphatidylserine (PS) binding peptide-peptoid hybrid PPS1.European journal of medicinal chemistry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
We describe an approach for engineering peptide-lipid nanoparticles that function similarly to high-density lipoprotein (HDL). Branched, multivalent constructs, bearing multiple 23- or 16-amino-acid peptides, were designed, synthesized, and combined with phospholipids to produce nanometer-scale discoidal HDL-like particles. A variety of biophysical techniques were employed to characterize the constructs, including size exclusion chromatography, analytical ultracentrifuge sedimentation, circular dichroism, transmission electron microscopy, and fluorescence spectroscopy. The nanoparticles functioned in vitro (human and mouse plasma) and in vivo (mice) to rapidly remodel large native HDLs into small lipid-poor HDL particles, which are key acceptors of cholesterol in reverse cholesterol transport. Fluorescent labeling studies showed that the constituents of the nanoparticles readily distributed into native HDLs, such that the peptide constructs coexisted with apolipoprotein A-I (apoA-I), the main structural protein in HDLs. Importantly, nanolipid particles containing multivalent peptides promoted efficient cellular cholesterol efflux and were functionally superior to those derived from monomeric apoA-I mimetic peptides. The multivalent peptide-lipid nanoparticles were also remarkably stable toward enzymatic digestion in vitro and displayed long half-lives and desirable pharmacokinetic profiles in mice, providing a real practical advantage over previously studied linear or tandem helical peptides. Encouragingly, a two-week exploratory efficacy study in a widely used animal model for atherosclerosis research (LDLr-null mice) using nanoparticles constructed from a trimeric peptide demonstrated an exceptional 50% reduction in the plasma total cholesterol levels compared to the control group. Altogether, the studies reported here point to an attractive avenue for designing synthetic, HDL-like nanoparticles, with potential for treating atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.